This poster, originally presented at AACR 2023, showcases data on our developmental progress in establishing an off-the-shelf platform for culture and scale-up of NK cells for therapeutic purposes. Development of a key NK assay for functional phenotyping is also demonstrated.

While NK and CAR-NK cells represent an attractive alternate modality to T and CAR T cell-based therapies, effective scale-up of NK cells is still considered a major obstacle towards achieving therapeutic efficacy. Our platform and scale-up experience help determine the combination of factors necessary for an optimized and robust scale-up process.

Download this poster to learn about how we can help streamline your cell therapy program journey to market.

About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.